



Hereditary diffuse gastric cancer: updated clinical practice guidelines

Vanessa R Blair, Maybelle McLeod, Fátima Carneiro, Daniel G Coit, Johanna L D'Addario, Jolanda M van Dieren, Kirsty L Harris, Nicoline Hoogerbrugge, Carla Oliveira, Rachel S van der Post, Julie Arnold, Patrick R Benusiglio, Tanya M Bisseling, Alex Boussioutas, Annemieke Cats, Amanda Charlton, Karen E Chelcun Schreiber, Jeremy L Davis, Massimiliano di Pietro, Rebecca C Fitzgerald, James M Ford, Kimberley Gamet, Irene Gullo, Richard H Hardwick, David G Huntsman, Pardeep Kaurah, Sonia S Kupfer, Andrew Latchford, Paul F Mansfield, Takeshi Nakajima, Susan Parry, Jeremy Rossaak, Haruhiko Sugimura, Magali Svrcek, Marc Tischkowitz, Toshikazu Ushijima, Hidetaka Yamada, Han-Kwang Yang, Adrian Claydon, Joana Figueiredo, Karyn Paringatai, Raquel Seruca, Nicola Bougen-Zhukov, Tom Brew, Simone Busija, Patricia Carneiro, Lynn DeGregorio, Helen Fisher, Erin Gardner, Tanis D Godwin, Katharine N Holm, Bostjan Humar, Caroline J Lintott, Elizabeth C Monroe, Mark D Muller, Enrique Norero, Yasmin Nouri, Joana Paredes, João M Sanches, Emily Schulpen, Ana S Ribeiro, Andrew Sporle, James Whitworth, Liying Zhang, Anthony E Reeve, Parry Guilford

Hereditary diffuse gastric cancer (HDGC) is an autosomal dominant cancer syndrome that is characterised by a high prevalence of diffuse gastric cancer and lobular breast cancer. It is largely caused by inactivating germline mutations in the tumour suppressor gene *CDH1*, although pathogenic variants in *CTNNA1* occur in a minority of families with HDGC. In this Policy Review, we present updated clinical practice guidelines for HDGC from the International Gastric Cancer Linkage Consortium (IGCLC), which recognise the emerging evidence of variability in gastric cancer risk between families with HDGC, the growing capability of endoscopic and histological surveillance in HDGC, and increased experience of managing long-term sequelae of total gastrectomy in young patients. To redress the balance between the accessibility, cost, and acceptance of genetic testing and the increased identification of pathogenic variant carriers, the HDGC genetic testing criteria have been relaxed, mainly through less restrictive age limits. Prophylactic total gastrectomy remains the recommended option for gastric cancer risk management in pathogenic *CDH1* variant carriers. However, there is increasing confidence from the IGCLC that endoscopic surveillance in expert centres can be safely offered to patients who wish to postpone surgery, or to those whose risk of developing gastric cancer is not well defined.

Introduction

Hereditary diffuse gastric cancer (HDGC) is a cancer syndrome characterised by a high prevalence of diffuse gastric cancer (DGC) and lobular breast cancer (LBC). HDGC was first described in an extended New Zealand Māori family in 1998,¹ and is now estimated to have a worldwide population incidence of 5–10 per 100 000 births. Most confirmed HDGC cases are caused by inactivating germline mutations in the *CDH1* tumour suppressor gene.² *CDH1* encodes E-cadherin, a transmembrane protein that is localised to the adherens junctions in epithelial tissues and has functions in cell to cell adhesion, tension sensing, and signal transduction.³ Mutations in a second adherens junction protein, α -catenin (*CTNNA1*), are also found in a small minority of HDGC cases.⁴

In the past 5 years the genetic testing landscape has been changing, with lower costs, increased accessibility, more public awareness, and greater adoption of cancer gene panels, particularly for breast cancer. For the *CDH1* gene, this change has led to the increased identification of genetic variants in individuals with a family history of breast cancer but little or no family history of gastric cancer, challenging the existing DGC-centric genetic testing criteria.⁵ This changing landscape, combined with deeper experience of both HDGC endoscopic surveillance and long-term follow-up after gastrectomy, has demanded an update to the previous International Gastric Cancer Linkage Consortium (IGCLC) management guidelines for HDGC published in 2015.⁶

Guideline development

From March 16 to 18, 2019, a group of 19 genetic researchers, seven pathologists, ten gastroenterologists, seven breast and gastric surgeons, seven clinical geneticists and genetic counsellors, a pharmacist, and 13 HDGC advocates or family members met in Wānaka, New Zealand to update the IGCLC guidelines and identify areas of emerging research in this field. The shared vision was to build a consensus for HDGC management that was tightly connected to the experience of families with HDGC. The group was identified through prior IGCLC engagement and active involvement in HDGC research, management, or advocacy. Focus groups reviewed new data and identified required updates to the guidelines and research priorities. After the Wānaka meeting, expert writing panels (geneticists, gastroenterologists, pathologists, surgeons, and advocates) achieved consensus within their specialties and drafted the manuscript. Because of the relatively low incidence of HDGC, randomised clinical trial data specific to HDGC are scarce. Therefore, as for other rare diseases, the recommendations in these guidelines have relied on consensus expert opinion, anecdotal evidence from experts, and observational studies, instead of using trial data.^{7,8} Therefore, the strength of the evidence for our recommendations is categorised as low to moderate according to the Grading of Recommendations, Assessment, Development, and Evaluation system.⁹ This categorisation means that further research is likely or very likely to have an important impact

Lancet Oncol 2020; 21: e386–97

Department of Surgery, University of Auckland, Auckland, New Zealand (V R Blair FRACS); St Marks Breast Centre, Auckland, New Zealand (V R Blair); Kimihauora Health and Research Clinic, Mt Maunganui, New Zealand (M McLeod, E Gardner); Instituto de Investigação e Inovação em Saúde & Institute of Molecular Pathology and Immunology of the University of Porto, Department of Pathology, University of Porto, Porto, Portugal (Prof F Carneiro MD, Prof C Oliveira PhD, I Gullo MD, J Figueiredo PhD, Prof R Seruca PhD, P Carneiro PhD, J Paredes PhD, A S Ribeiro PhD); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical School, New York, NY, USA (Prof D G Coit MD); HereditaryDiffuseGastricCancer.org, Madison, WI, USA (J L D'Addario MHS, K E Chelcun Schreiber); Department of Gastrointestinal Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands (J M van Dieren MD, A Cats MD); Brisbane, QLD, Australia (K L Harris BPharm, H Fisher DipEd); Department of Human Genetics (Prof N Hoogerbrugge MD), Department of Pathology (R S van der Post MD), and Department of Gastroenterology (T M Bisseling MD), Radboud University Medical Centre, Nijmegen, Netherlands; New Zealand Familial Gastrointestinal Cancer Service (J Arnold, S Parry MBChB), Department of Histopathology (A Charlton MBChB), and

Genetic Health Service
 New Zealand Northern Hub
 (K Gamet), Auckland Hospital,
 Auckland, New Zealand;
 Consultation d'Oncogénétique,
 Unité Fonctionnelle
 d'Oncogénétique,
 Département de Génétique,
 DMU BioGeM, Groupe
 Hospitalier Pitié-Salpêtrière,
 Sorbonne Université, Paris,
 France (P R Benusiglio MD);
 Department of Medicine, Royal
 Melbourne Hospital and
 Sir Peter MacCallum
 Department of Oncology,
 University of Melbourne,
 Melbourne, VIC, Australia
 (Prof A Boussioutas MBBS);
 Center for Cancer Research,
 National Cancer Institute,
 National Institutes of Health,
 Bethesda, MD, USA
 (J L Davis MD); Medical Research
 Council Cancer Unit
 (M di Pietro MD,
 Prof R C Fitzgerald MD)
 and Department of Medical
 Genetics, National Institute for
 Health Research Cambridge
 Biomedical Research Centre
 (M Tischkowitz MD,
 J Whitworth PhD), University of
 Cambridge, Cambridge, UK;
 Division of Oncology,
 Departments of Medicine and
 Genetics, Stanford University
 School of Medicine, Stanford,
 CA, USA (Prof J M Ford MD);
 Cambridge University
 Hospitals National Health
 Service Foundation Trust,
 Cambridge, UK
 (R H Hardwick FRCS);
 Department of Pathology and
 Laboratory Medicine
 (Prof D G Huntsman MD) and
 Department of Medical
 Genetics (P Kaurah PhD),
 University of British Columbia,
 Vancouver, BC, Canada;
 Hereditary Cancer Program,
 British Columbia Cancer,
 Vancouver, BC, Canada
 (P Kaurah); Section of
 Gastroenterology, Nutrition
 and Hepatology, University of
 Chicago, Chicago, IL, USA
 (S S Kupfer MD); St Mark's
 Hospital, London, UK
 (A Latchford MD); Department
 of Cancer and Surgery, Imperial
 College, London, UK
 (A Latchford); University of
 Texas MD Anderson Cancer
 Center, Houston, TX, USA
 (Prof P F Mansfield MD);
 Department of Clinical Genetic
 Oncology, Cancer Institute
 Hospital, Tokyo, Japan
 (T Nakajima MD); Department




Figure 1: Management of individuals and families who either meet the revised HDGC genetic testing criteria or have had a pathogenic CDH1 variant identified through another route

DGC=diffuse gastric cancer. HDGC=hereditary diffuse gastric cancer. LBC=lobular breast cancer. HLBC=hereditary lobular breast cancer. *See text for full description of CTNNA1 pathway.

on our confidence in the estimate of the effect addressed by the recommendation.

Scope

These guidelines address the management of individuals and families who meet the revised genetic testing criteria for HDGC, and individuals with a pathogenic or likely pathogenic CDH1 or CTNNA1 variant¹⁰ identified through other routes, including direct-to-consumer testing (figure 1). The management of sporadic DGC and LBC, familial intestinal gastric cancer,¹¹ gastric adenocarcinoma and proximal polyposis of the stomach, and familial gastric or breast cancer associated with other predisposition genes, is not covered in this update.

Definitions

In this Policy Review, the term pathogenic variant refers collectively to both likely pathogenic and pathogenic variants.¹² Rather than using a clinical definition, HDGC is now defined by the presence of a pathogenic germline CDH1 or CTNNA1 variant in either an isolated individual with DGC, or in a family with one or more DGC cases in first-degree or second-degree relatives. Similarly, hereditary lobular breast cancer (HLBC) is defined in this context by the presence of a pathogenic CDH1 variant in either an isolated individual with LBC, or a family with one or more LBC cases in first-degree or second-degree relatives, but no known DGC in either situation. By definition, families with HLBC are recategorised as

having HDGC if DGC (or a precursor lesion of HDGC)¹³ is identified in a family member at a later date. The distinction between HDGC and HLBC acknowledges the likelihood that not all families with pathogenic *CDH1* variants are equally at risk of DGC.^{14,15} Families that are considered to be HDGC-like fulfil HDGC genetic testing family criteria 1 or 2 (panel 1), but have no identified pathogenic *CDH1* or *CTNNA1* variant. Thus, families must have at least one confirmed case of DGC, and another gastric cancer or LBC in first-degree or second-degree relatives, to be classified as being HDGC-like.

Genetic testing and penetrance HDGC genetic testing criteria

Genetic testing criteria must balance health-care-related costs, public acceptance of the test, and the psychological burden imposed on the tested population, against the benefit of identifying more asymptomatic individuals at high risk. Accordingly, the 2020 HDGC genetic testing criteria have been relaxed, mainly through changes to age restrictions (panel 1). For example, the HDGC screening threshold age for isolated DGC cases is increased from younger than 40 years to younger than 50 years. Similarly, the threshold age for testing of women with bilateral LBC is increased from younger than 50 to younger than 70 years, with an expected yield of pathogenic *CDH1* variants of approximately 7%.¹⁶ Furthermore, because approximately 13% of the New Zealand Māori population with advanced DGC have pathogenic germline *CDH1* variants,¹⁷ all Māori with confirmed DGC are now recommended to undergo *CDH1* genetic testing. The 2015 criteria that recommended testing in individuals with a personal or family history of cleft lip or cleft palate and DGC,¹⁸ or with HDGC precursor lesions, remain.⁶ Individuals who meet the criteria for HDGC genetic testing should first have *CDH1* analysed and, if no variant is identified, be considered for *CTNNA1* analysis.

In Japan and South Korea, it is recommended that the Japanese Gastric Cancer Association classification¹⁹ of signet ring cell carcinoma is used for DGC instead of the Lauren classification of DGC.²⁰ Index cases from families with newly identified HDGC who present with advanced gastric cancer can, however, display features of the non-solid type poorly differentiated adenocarcinoma subclass. Patients with multiple signet ring cell carcinoma lesions, identified either endoscopically or in the gastrectomy specimen, are also recommended to be offered *CDH1* genetic testing.

Genetic counselling

In individuals meeting genetic testing criteria, testing should be offered from the legal age of consent (generally 16–18 years). Testing of younger family members can also be considered based on family history.²¹ Where possible, genetic counselling for HDGC and HLBC should include evaluation of a three-generation family history, any history of cleft lip or cleft palate, and

Panel 1: 2020 hereditary diffuse gastric cancer (HDGC) genetic testing criteria

CDH1 testing is recommended when one of the following criteria have been met and cancer diagnoses have been confirmed. When a criterion involves two or more cancers, at least one cancer should have confirmed histology. Where possible, other relevant cancers should also be confirmed. Histologically confirmed intestinal-type gastric cancer and non-lobular breast cancer cases should not be used to fulfil testing criteria, because these cancers are not part of HDGC. Individuals who fulfil criteria for genetic testing but are found to be negative for a *CDH1* variant should subsequently be considered for *CTNNA1* analysis.

Family criteria*

- 1 ≥2 cases of gastric cancer in family regardless of age, with at least one diffuse gastric cancer (DGC)
- 2 ≥1 case of DGC at any age, and ≥1 case of lobular breast cancer at age <70 years, in different family members
- 3 ≥2 cases of lobular breast cancer in family members <50 years of age

Individual criteria

- 4 DGC at age <50 years
- 5 DGC at any age in individuals of Māori ethnicity
- 6 DGC at any age in individuals with a personal or family history (first-degree relative) of cleft lip or cleft palate
- 7 History of DGC and lobular breast cancer, both diagnosed at age <70 years
- 8 Bilateral lobular breast cancer, diagnosed at age <70 years
- 9 Gastric in situ signet ring cells or pagetoid spread of signet ring cells in individuals <50 years of age

*Family members must be first-degree or second-degree blood relatives of each other. Where possible, test an affected person. If there are no living affected relatives, consider tissue testing (tumour tissue or healthy tissue) from an affected deceased relative. If these options are not possible, consider indirect testing in unaffected family members.

histopathological confirmation of cancer diagnoses or any precursor lesions. Counselling should pay particular attention to the individual's psychosocial needs.²² Counsellors should help patients to understand the importance of disclosing their diagnosis to family members at risk, and offer assistance to implement a communication plan. It can be helpful to meet with the wider family to discuss different perspectives and ensure consistent information is given to other family members.

Comprehensive, multidisciplinary discussion around the benefits and risks of gastric and breast cancer surveillance and risk-reducing surgery, including the long-term sequelae of prophylactic total gastrectomy, is required.⁶ Most individuals who have undergone this surgery express little or no regret afterwards.^{23–25} Both preimplantation genetic testing and prenatal diagnoses should be discussed during counselling and made available to *CDH1* pathogenic variant carriers, and adults of childbearing age should be offered reproductive genetic advice.

Multigene panel tests

With the widespread introduction of cancer gene panels, unexpected *CDH1* variants have been identified in individuals who do not have phenotypes suggestive of HDGC,⁵ creating a substantial challenge for patients and clinicians.^{5,26,27} Individuals undergoing panel tests that

of Surgery (J Rossaak FRACS) and Department of Gastroenterology (A Claydon MBChB), Tauranga Hospital, Tauranga, New Zealand; Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan (Prof H Sugimura MD, H Yamada PhD); Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Department of Pathology, Hôpital Saint-Antoine, Paris, France (Prof M Svrcek MD); Division of Epigenomics, National Cancer Centre Research Institute, Tokyo, Japan (T Ushijima MD); Seoul National University Hospital, Seoul, South Korea (Prof H-K Yang); Te Tumu School of Māori, Pacific and Indigenous Studies (K Paringatai PhD), Cancer Genetics Laboratory, Te Aho Matatū, Department of Biochemistry (N Bougen-Zhukov PhD, T Brew MSc, T D Godwin MSc, Y Nouri MSc, E Schulpen BSc [Hons]),

Prof A E Reeve PhD,
 Prof P Guilford PhD, and
 Healthier Lives National
 Science Challenge
 (A Sporle MA), University of
 Otago, Dunedin, New Zealand;
 No Stomach for Cancer,
 Madison, WI, USA (S Busija);
 DeGregorio Family Foundation,
 New York, NY, USA
 (L DeGregorio MBA,
 E C Monroe MS); Department of
 Biochemistry and Molecular
 Medicine, University of
 California Davis School of
 Medicine, Davis, CA, USA
 (K N Holm BS); Laboratory of
 the Swiss Hepato-Pancreato-
 Biliary and Transplantation
 Centre, Department of Surgery,
 University Hospital Zürich,
 Zürich, Switzerland
 (B Humar PhD); Genetic Health
 Service New Zealand South
 Island Hub, Christchurch
 Hospital, Christchurch,
 New Zealand (C J Lintott PhD);
 Mt Maunganui, New Zealand
 (M D Müller MBChB);
 Esophagogastric Surgery Unit,
 Digestive Surgery Department,
 Hospital Dr Sotero del Rio,
 Pontificia Universidad Católica
 de Chile, Santiago, Chile
 (E Norero MD); Institute for
 Systems and Robotics,
 Instituto Superior Técnico,
 Lisbon, Portugal
 (J M Sanches PhD); and
 Department of Pathology and
 Laboratory Medicine, UCLA
 David Geffen School of
 Medicine, Los Angeles, CA,
 USA (L Zhang MD)

Correspondence to:
 Prof Parry Guilford, Cancer
 Genetics Laboratory,
 Te Aho Matatū, Department of
 Biochemistry, University of
 Otago, Dunedin 9016,
 New Zealand
 parry.guilford@otago.ac.nz

See Online for appendix

include *CDH1* and *CTNNA1* should receive genetic counselling, but with added emphasis on the uncertain risks that exist in families with no history of DGC. *CDH1* pathogenic variants appear to only be associated with LBC, and not invasive breast carcinoma of no special type (formerly designated as ductal breast cancer), nor other rare types of breast cancer; therefore, *CDH1* gene testing should only be contemplated in women with confirmed LBC.

Genetic testing

Genetic testing for germline variants of *CDH1* and *CTNNA1* should be performed in certified molecular diagnostic laboratories—eg, Clinical Laboratory Improvement Amendments (CLIA) approved, ISO 15189 accredited, or equivalent. Genetic analysis should include sequencing of the entire open reading frame, including intron–exon boundaries, and copy number analysis of individual exons to detect deletions or duplications. *CDH1* large deletions (including exons) are rare, accounting for fewer than 5% of pathogenic variants.²⁸ Any positive test results from direct-to-consumer testing must be validated in a certified laboratory. Variant interpretation should be performed using the American College of Medical Genetics and Genomics and Association for Molecular Pathology guidelines.¹⁰ It is important to note that variants described as “likely pathogenic” have a 90% likelihood of pathogenicity;¹² therefore, a risk remains that the variant might be later reclassified as benign. There is no indication for presymptomatic testing in families carrying a variant of unknown significance, or a benign or likely benign variant. Particular care needs to be taken with the interpretation of missense variants; according to the *CDH1* variant curation guidelines, the currently published in vitro or in silico functional assays cannot be used to predict pathogenicity of *CDH1* missense variants,¹⁰ and therefore these assays should not be used for *CDH1* variant classification until they are clinically validated. However, in-vitro assays that assess the effects of *CDH1* missense variants on E-cadherin levels, localisation, and function remain important research tools.²⁹

Other than *CTNNA1*, additional genes that predispose specifically to DGC but not intestinal-type gastric cancer have not been identified, despite panel and whole-exome-sequencing efforts.^{2,30,31} Increasing evidence suggests that germline pathogenic variants in *PALB2* might be the cause of increased gastric cancer risk in some families, although these variants are not confined to the diffuse subtype of gastric cancer.^{31,32} *PALB2* testing could be considered in families where the increased risk remains unexplained, alongside testing for other genes associated with an increased risk of gastric cancer—eg, *ATM*, *BRCA2*,² the Lynch syndrome genes, *APC*, and *TP53*.

Cancer risk in carriers of *CDH1* pathogenic variants

Recent studies have shown that gastric cancer penetrance estimates for carriers of *CDH1* pathogenic variants are

influenced by the clinical criteria used for the ascertainment of affected families (appendix p 1).^{14,15} Hansford and colleagues² estimated the cumulative risk of gastric cancer by 80 years of age to be 70% in male carriers and 56% in female carriers, using data from families who all met the 2010 HDGC clinical criteria.³³ However, a recent report—in which only 37% of families with *CDH1* pathogenic variants met the less stringent 2015 HDGC clinical criteria—estimated the gastric cancer penetrance to be 42% for males and 33% for females.¹⁴ Lower gastric cancer risk was also observed in a study in which 39% of families met the 2015 HDGC criteria.¹⁵ Clearly, DGC risk varies between families and therefore family history should be considered when estimating an individual carrier’s risk. Notably, estimates of female breast cancer risk, which have ranged from 39% to 55% have been more consistent between studies (appendix p 1). Since this variation in gastric cancer risk is likely to be strongly influenced by individual genetic background and lifestyle factors, it should not be assumed that the historical risk will equal the risk faced by younger generations.

Whether or not the penetrance of gastric cancer from pathogenic missense *CDH1* variants is substantially lower than that from truncating variants remains unknown, although considerable variability between different missense variants would be expected. Finally, no strong evidence exists to suggest that the risk of other cancer types is significantly increased in individuals with a *CDH1* pathogenic variant.^{2,14,34} In particular, there is insufficient evidence to recommend additional colorectal cancer screening beyond adherence to national population screening guidelines.⁶

Clinical practice recommendations

HDGC

CDH1 variant carriers from families with confirmed HDGC should be advised to consider prophylactic total gastrectomy, irrespective of endoscopic findings (figure 1). Where possible, surgery is recommended in early adulthood, generally between 20 and 30 years of age.⁶ Given the increased perioperative risks and prolonged recovery associated with older age, prophylactic total gastrectomy is not recommended in patients older than 70 years unless there are noteworthy mitigating circumstances. For individuals declining or wishing to postpone gastrectomy, yearly endoscopy by experienced endoscopists with knowledge of HDGC is recommended (appendix p 2). It is also recommended that *Helicobacter pylori* is eradicated if present.³⁵ LBC risk should be managed with either yearly surveillance or bilateral risk-reducing mastectomy.

Little is known about the penetrance of pathogenic *CTNNA1* variants.³⁶ However, intramucosal DGC foci have been observed in prophylactic total gastrectomy specimens from young asymptomatic carriers of these variants, suggesting that pathogenic variants in both *CDH1* and *CTNNA1* could have similar implications

regarding DGC risk.^{4,37} Therefore, asymptomatic carriers of *CTNNA1* pathogenic variants are recommended to undergo yearly endoscopic surveillance in an expert centre, with prophylactic total gastrectomy being considered depending on the results of the biopsies and the penetrance of DGC in the family history. Breast cancer surveillance can be considered on a case-by-case basis.³⁶

HLBC

The management of families with HLBC, and other individuals with a pathogenic *CDH1* variant but no family history of DGC, is not straightforward.²⁶ It is probable that DGC penetrance is significantly lower in these groups,^{14,15} although more data are required for accurate estimates. Signet ring cell carcinomas have, however, been reported in prophylactic total gastrectomy specimens from carriers with no family history of DGC.³⁸ Therefore, yearly endoscopic surveillance should be offered to these groups, but prophylactic total gastrectomy should also be considered, giving careful attention to the uncertain gastric cancer risk. LBC risk in families with HLBC should be managed with either yearly surveillance or bilateral risk-reducing mastectomy. Yearly breast cancer surveillance is recommended in pathogenic *CDH1* variant carriers without a family history of DGC or breast cancer.

HDGC-like

Affected individuals from families that are HDGC-like, and their first degree relatives, may be considered for yearly endoscopic surveillance for at least 2 years (figure 1). Surveillance should begin at 40 years of age, or 10 years prior to the earliest case of gastric cancer within the family, with a minimum age of 18 years. Since a positive biopsy is most likely during the first endoscopy,^{39,40} surveillance intervals can be prolonged at the discretion of the endoscopist after 2 years, based on individual findings in earlier endoscopies and on the family history.³⁹ Prophylactic total gastrectomy is not advised when endoscopies are negative, because of the uncertainty surrounding the level of individual risk of developing cancer. Individualised breast cancer risk assessment and surveillance are also recommended.

There are few data to support surveillance endoscopy in first-degree relatives of young individuals with DGC in the absence of any family history or pathogenic *CDH1* or *CTNNA1* variant.

CDH1 variant of unknown significance

Individuals who have a *CDH1* variant of unknown significance^{10,12} (a genetic sequence with an unclear association to disease) and a family or personal history of DGC may be considered for annual endoscopic surveillance for at least 2 years as for those families that are HDGC-like. However, a paucity of data resulted in a lack of consensus regarding the clinical utility of surveillance in these groups. Accordingly, surveillance endoscopy should ideally be done as part of a research study. A

prophylactic total gastrectomy is not advised for variant of unknown significance carriers when endoscopies are negative. Individualised breast cancer risk assessment and surveillance are recommended.

Breast surveillance and bilateral risk-reducing mastectomy

Hereditary breast cancer guidelines draw heavily on the evidence base from individuals with pathogenic *BRCA1* and *BRCA2* variants, most of whom will have had invasive breast carcinoma of no special type. Although these guidelines are useful, the hallmark of pathogenic *CDH1* variant-related breast cancer is LBC, a phenotype with specific clinical and radiological ramifications, as recently reviewed.⁴¹ The recommendations outlined here (panel 2) are more specifically tailored to the risk and management of LBC, and are consistent with existing guidelines, including those from eviQ,⁴⁶ the National Institute for Health and Care Excellence,⁴⁷ the European Society for Medical Oncology,⁴⁸ and the National Comprehensive Cancer Network⁴⁹ (appendix p 4).

Breast surveillance for HDGC and HLBC should start at 30 years of age, with yearly MRI from 30–50 years of age, and potentially for longer. The benefit of adding mammography to MRI in young women, who generally have denser breasts, is uncertain, and limiting mammography until the age of 40–50 years has been suggested for *BRCA1* and *BRCA2* mutation carriers.⁴⁴ Although this approach could be considered on an individual basis, yearly mammography from 35 years of age is acceptable. Supplementary screening ultrasound in dense breasts is not without controversy,⁵⁰ but has a role,⁵¹ especially when MRI is not available, or is contraindicated or declined.

When LBC is detected, treatment should follow standard practice.^{41,52} A woman with a *CDH1* pathogenic variant could choose breast-conserving surgery, however bilateral risk-reducing mastectomy should also be considered, as for any woman at high risk for breast cancer. Skin and nipple-sparing mastectomy with immediate reconstruction is acceptable, provided adequate surgical margins are achievable.⁴⁷ A finding of lobular carcinoma in situ, which is typically a coincidental finding on biopsies being done for another reason, does not mandate risk-reducing mastectomy; however, this option should be discussed, alongside the option for ongoing surveillance and chemoprevention (panel 2).

In women with invasive breast carcinoma of no special type and no family history of LBC or DGC, who are found to carry a pathogenic *CDH1* variant from a panel test, management is challenging. If pathological review excludes misclassification, this is likely to be a sporadic cancer and breast-conserving surgery is acceptable, with ongoing surveillance.

Endoscopic surveillance

When endoscopic surveillance is offered (panel 3), the limitations of the procedure should be discussed—namely

Panel 2: Breast cancer surveillance and risk-reducing mastectomy in hereditary diffuse gastric cancer (HDGC) and hereditary lobular breast cancer (HLBC)

Discussions regarding the option for surveillance versus bilateral risk-reducing mastectomy need to cover key information to facilitate shared decision-making and informed consent, including the following points:

- The scant knowledge about breast cancer in HDGC and HLBC
- The paucity of prospective data on imaging for lobular breast cancer (LBC) in a screening setting⁴²
- The individual's breast density on mammogram and background breast enhancement on MRI, and the potential impact of these on the sensitivity of detection of lobular breast cancer
- The individual's experience of breast surveillance, particularly tolerance of MRI
- What to expect if lobular breast cancer is detected during surveillance
- The option for chemoprevention
- Information about gadolinium contrast in line with recommendations from radiology societies⁴³
- The potential harms of surveillance, in line with consent practices in breast screening programmes—eg, recall rate for further assessment after MRI

Breast cancer surveillance

- Surveillance should begin at age 30 years and include yearly clinical breast examination
- The concept of breast awareness should be explained, with education about the clinical features of lobular breast cancer—eg, indrawn nipple or skin tethering, thickening in breast tissue, or subtle change in breast contour, shape, or size
- Modifiable risk factors (eg, alcohol intake, exercise, and weight) should be discussed
- Yearly breast MRI with contrast is recommended:
 - Should begin at age 30 years, but the age when it should cease is not clear; there might be benefit to continuing beyond 50 years of age, even in non-dense breasts, because of the greater sensitivity of MRI in detection of lobular breast cancer

- Should ideally be performed mid-cycle (days 10–14) when background breast enhancement is lowest
- There is no evidence to support use of abbreviated MRI
- Yearly mammography from age 40 years is recommended but can be considered from 35 to 40 years on a case-by-case basis
 - Mammography alone is inadequate for screening in HDGC
 - Mammography is generally not recommended in those younger than 35 years unless there are clinically suspicious findings
 - The extra benefit of mammogram at the time of MRI is likely to be low, and the option to omit it can be considered on a case-by-case basis⁴⁴
- Ultrasound has a role in women who are unable to have MRI or have no access to MRI
 - Should be combined with yearly mammography
 - Has a role in investigating symptoms between screening intervals

Bilateral risk-reducing mastectomy

- Can be considered in HLBC and HDGC
- Is not usually recommended in those younger than 30 years, nor generally in those older than 60 years of age

Chemoprevention

- In women at elevated risk of breast cancer, chemoprevention studies with selective oestrogen receptor modulators (pre-menopausal women) or aromatase inhibitors (post-menopausal women) show about a 50% risk reduction. Chemoprevention benefit is higher in some lobular carcinoma in situ studies,⁴⁵ although there have been no chemoprevention studies specifically for lobular breast cancer.
- Therapeutic levels of chemopreventative agents could be compromised after total gastrectomy
- The side-effects of endocrine therapy on quality of life can affect uptake and compliance, and discussion of these side-effects with a breast specialist is necessary

that DGC can be difficult to visualise on endoscopy, and it is unknown whether or not surveillance in this context positively affects life expectancy. The upper age limit for surveillance endoscopy depends on the patient's fitness for gastrectomy, but in general, surveillance in those older than the age of 70 years is probably not purposeful.

Although surveillance in expert centres suggests that superficial signet ring cell carcinoma lesions can be indolent for several years, the rate of progression is unpredictable.³⁹ If patients prefer to undergo surveillance, they must be informed that this could delay identification and treatment of gastric cancer. It is beneficial to build long-term relationships with patients to support them in their decision-making process. Yearly endoscopic surveillance should be performed in a centre with demonstrable

expertise in recognition of signet ring cell carcinoma lesions. All surveillance programmes should be audited and ideally included in a prospective clinical trial.

Recent studies from expert centres in HDGC surveillance endoscopy report that signet ring cell carcinoma lesions are detected in gastric biopsies in 40–61% of these carriers of *CDH1* variants, most often at the baseline endoscopy (van Dieren J, Netherlands Cancer Institute, personal communication),^{38,39} although older studies report a lower detection rate of 9–16%.^{33–36} High-definition endoscopes, image-enhancing techniques (eg, narrow band imaging), and the experience of the endoscopist and pathologist are all factors likely to be related to the increase in signet ring cell carcinoma detection rates in more recent studies.

The a priori chance of having at least one signet ring cell carcinoma lesion in the total gastrectomy specimen from a carrier of a *CDH1* pathogenic variant is 95%.⁵⁷ Consequently, the clinical relevance of a few superficial (stage T1a) signet ring cell carcinoma lesions in endoscopic biopsies is questionable, especially since these superficial lesions can display a very indolent behaviour.⁵⁸ Therefore, the goal of surveillance is not to detect every single superficial lesion. However, for patients who wish to postpone surgery, the main goals are to exclude deeper infiltrating lesions; to detect large or numerous signet ring carcinoma T1a lesions, as these patients probably have a higher chance of developing higher stage lesions; and to assess changing histology and endoscopic appearance, which can signal more malignant behaviour (van Dieren J, personal communication).²¹ A comparison between a superficial intramucosal pT1a lesion and a deeper intramucosal T1a lesion is shown in figures 2A–D, from both the endoscopic and histological perspectives.

Staging investigations are advised if erosive lesions, lesions with a disturbed vascular and pit pattern, or histopathological signs of invasion into or beyond the muscularis mucosae, are identified. If a signet ring cell carcinoma lesion with none of these risk indicators is identified, individual circumstances, such as age and comorbidity, might mean postponement of a prophylactic total gastrectomy is recommended after multidisciplinary team review. However, in this situation, intensified endoscopic monitoring for disease progression is advised, with endoscopy every 6 months.

Prophylactic total gastrectomy

Patient selection and preparation

The decision to proceed to prophylactic total gastrectomy should be careful and deliberate. The patient, family, and care coordinators must be involved early in the decision-making process. Discussions should cover the risks of the operation, the long-term sequelae, and optimally include the individual surgeon's or institution's outcomes for this procedure. Patients should be offered preoperative psychological counselling to afford them an opportunity to express any concerns that might not have surfaced previously. The active engagement of patients who have recovered from prophylactic gastrectomy, to act as navigators, can help set realistic expectations about surgery and recovery, and provide a source of ongoing support throughout the process.

It is critical to assess and acknowledge an individual patient's competing risks (medical, oncological, and psychosocial) when the care plan is formulated. Untreated addictions (eg, food, drug, alcohol, or tobacco) will complicate recovery from gastrectomy and should be addressed preoperatively. If possible, gastrectomy should be avoided in patients with serious eating disorders (eg, anorexia or bulimia), or with other psychiatric diagnoses refractory to treatment that impair daily life (eg, bipolar disorder or severe depression) and could

Panel 3: Endoscopy key recommendations

- Surveillance should be conducted in expert centres familiar with hereditary diffuse gastric cancer (HDGC)
- Surveillance instead of a prophylactic total gastrectomy can be considered depending on individual circumstances and wishes of pathogenic variant carriers (see definitions)
- Surveillance instead of a prophylactic total gastrectomy should be considered in pathogenic variant carriers with an unclear risk for diffuse gastric cancer (DGC), such as those who have not met HDGC genetic testing criteria or who carry pathogenic *CTNNA1* mutations
- Surveillance may be considered for individuals with a family history or personal history of DGC and a *CDH1* variant of unknown significance, and affected individuals from families that are HDGC-like and their first degree relatives; after two negative endoscopies, surveillance intervals can be prolonged at the discretion of the endoscopist, based on individual findings in earlier endoscopies and on the family history
- Surveillance endoscopies should include both targeted and random biopsies
- The number of recommended random biopsies is 28–30 (three to five cardia, five fundus, ten body, five transition zone, and five antrum)
- We recommend gastric inlet patches in the oesophagus are registered, inspected, and biopsied
- All patients undergoing surveillance should be fully informed about the limitations of endoscopy

interfere with both the decision about surgery, and subsequent recovery.

Patients proceeding to gastrectomy should have a baseline endoscopy performed before surgery to ensure there is no endoscopically evident cancer, since this would require staging investigations. Endoscopy can also identify other coincidental pathology, such as Barrett's oesophagus, which might alter the proximal extent of the resection.

Surgery

Prophylactic total gastrectomy should only be offered by surgeons working in facilities with transparent outcome data and demonstrable capability in preventing, recognising, and managing the complications of total gastrectomy. Ideally, these facilities should be experienced in treating *CDH1* variant carriers. National guidelines for surgery provision differ across the world, but facilities undertaking prophylactic total gastrectomy should adhere to relevant local professional standards. The surgical approach is not as important as the experience of the surgeon, with minimally invasive approaches (laparoscopic and robotic) impacting more on short-term rather than long-term outcomes, when compared with open surgery.^{59,60}

Gastrectomy should be total, with intraoperative confirmation of oesophageal squamous mucosa in




Figure 2: Endoscopic and histopathological images of HDGC gastric lesions

(A, B) Superficial pT1a signet ring cell carcinoma focus, with (A) endoscopy of non-elevated pale lesion and (B) corresponding histology of signet ring cells with indolent phenotype superficially in the lamina propria. (C, D) Intramucosal pT1a signet ring cell carcinoma focus with invasion into the deeper lamina propria, with (C) endoscopy of 1 mm erosive lesion in middle of coarse pit pattern and (D) corresponding histology showing deeper invasion of signet ring cells almost reaching the muscularis mucosae (asterisk). (E, F) Precursor gastric lesions in HDGC, with (E) in situ signet ring cell carcinoma (dotted line) displaying signet ring cells within basal membrane and (F) pagetoid spread of signet ring cells (arrows) below the preserved epithelium. (G, H) Invasive HDGC gastric lesions within the lamina propria, with (G) intramucosal signet ring cell carcinoma focus (haematoxylin and eosin stain) and (H) periodic acid-schiff-diastase staining. (I, J) Intratumoural heterogeneity displayed in two biopsies from the same tumour, with (I) DGC with typical signet ring cells (indolent phenotype) and (J) DGC with pleomorphic, bizarre cells (aggressive phenotype). (K, L) Advanced DGC, with (K) invasion of gastric wall with prominent desmoplastic response and (L) peritoneal metastasis. HDGC=hereditary diffuse gastric cancer. DGC=diffuse gastric cancer.

the proximal margin and duodenal mucosa in the distal margin. Perigastric lymph node metastases are exceedingly uncommon in patients undergoing true prophylactic total gastrectomy (ie, in the absence of biopsy-proven DGC). As such, a deliberate extended D2 lymphadenectomy is not required and is generally discouraged to minimise postoperative morbidity. To avoid the potential of understaging the rare patient with a previously unappreciated T2 tumour, a reasonable compromise would be to perform a perigastric D1 lymph node dissection at the time of gastrectomy. Further detail on the surgical procedure and recovery are provided in appendix p 5.

Histopathology

Histopathology suggesting a diagnosis of HDGC

Two preinvasive or precursor lesions of signet ring cell carcinoma have been recognised exclusively in *CDH1* pathogenic variant carriers and are important clues to the diagnosis of HDGC. First, in situ signet ring cell carcinoma, corresponding to the presence of signet cells with hyperchromatic and depolarised nuclei within the basal membrane of a gland, replacing the normal cells of the gland; second, pagetoid spread of a row of signet cells below the preserved epithelium of glands and

foveolae, and also within the basal membrane (figure 2E, F).¹³ The predominant lesions in HDGC however are tiny foci of typical signet cells, usually confined to the superficial lamina propria, without infiltration beneath the muscularis mucosae. The neoplastic cells are usually small in the deep level at the neck gland zone, and enlarge towards the surface (figure 2G–I). Endoscopic biopsy specimens from *CDH1* pathogenic variant carriers can also have features of non-signet cell poorly cohesive (diffuse) gastric cancer with a so-called aggressive phenotype, represented by pleomorphic or bizarre, and diffusely infiltrative, cells (figure 2J). These features are highly suggestive of disease progression and should be described in the pathology report, to prompt staging and clinical intervention.²¹ Criteria for the identification of signet ring cell lesions should be followed strictly to diminish the risk of over-diagnosing non-specific changes, and to distinguish them from mimickers of precursor lesions or signet ring cell carcinoma (appendix p 6).^{61,62}

Histopathology of advanced HDGC

Similar to sporadic DGC, advanced HDGC predominantly presents as linitis plastica, with infiltration of the gastric wall by atypical cells with diffuse growth, and also cords, microglands, and small mucin lakes (figure 2K, L). A component of typical signet ring cells might also be seen.

Histopathology of prophylactic gastrectomies

The macroscopic examination of prophylactic total gastrectomy specimens should follow a specific protocol (appendix p 7), and a checklist is proposed for histological examination (appendix p 8). Both WHO (2019)⁶³ and Lauren²⁰ classifications should be used. Surgical margin analysis is mandatory to confirm that there is no residual gastric mucosa or tumour at the margins. The risk of developing signet ring cell carcinoma in oesophageal cardiac-type glands is unknown, and the risk is very low in heterotopic gastric mucosa in the duodenum.⁶⁴ To provide flexibility between routine clinical histopathology and research requirements, a three-level histopathology protocol is proposed, ranging from the minimum necessary for patient care, to total gastric embedding and mapping (appendix p 9).

Histopathology of *CDH1*-related breast cancer

In risk-reducing mastectomies from *CDH1* variant carriers, bilateral widespread foci of atypical lobular hyperplasia, lobular carcinoma in situ, and small foci of invasive LBC, have been detected (appendix p 10).⁶⁵ No unique histopathological or immunohistochemical findings distinguish *CDH1*-related LBC from sporadic LBC. Carriers of pathogenic *CDH1* variants have been diagnosed with invasive breast carcinoma of no special type,^{5,34} although these are likely to be coincidental sporadic cancers. Since LBC can be misclassified, it is

| | Recommendation |
|----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Early dumping (15–30 min postprandial) | Smaller meals, chewed well and eaten slowly; avoid drinking with meals |
| Late dumping (90 min to 3 h postprandial) | Meals with low sugar and high protein content; eat multiple small portions (six to eight a day); avoid drinking with meals |
| Lactose intolerance | Milk alternatives, lactase supplements |
| Fat malabsorption | Low-fat diet; consider addition of pancreatic enzymes; monitor blood levels of fat-soluble vitamins (A, D, E, and K); start vitamin D supplementation |
| Small bowel bacterial overgrowth or blind loop syndrome | Antibiotics with or without surgery |
| Dysphagia and anastomotic strictures | Smaller bites with deliberate mastication; upper endoscopy with balloon dilatation |
| Increased or decreased response to solid oral medication | Use alternate dosage forms (liquids; injections; or chewable, sublingual, dispersible tablets); open capsules and crush tablets if safe to do so; prescribe immediate release tablets (cf, controlled release preparations); avoid the oral contraceptive pill (use implant or intrauterine device); avoid gastrointestinal irritant drugs (eg, aspirin, non-steroidal anti-inflammatory drugs, oral bisphosphonates, and some antibiotics); avoid medication requiring acidic environment for absorption; lifelong monitoring of drug levels, markers, and metabolites, if possible, and assessment of desired outcomes by clinical observation and patient self-report |
| Increased effects of alcohol | Exert caution, avoid taking other CNS depressants, do not drive or operate heavy machinery; regular assessment of drinking patterns and behaviours; screening for alcohol use disorders |
| Nutritional deficiencies | High potency multivitamin with additional vitamin B12, iron, and calcium citrate supplements (iron and calcium separated by 4–5 h); correct dosing of vitamin B12 is essential; ⁶⁹ for iron-deficiency anaemia, iron infusions (cf, oral supplements) |
| Osteopenia or osteoporosis | Regular bone density scans (baseline then every 2–5 years); ensure adequate supplementation of calcium citrate (in divided doses) and vitamin D; tailored, weight-bearing exercises; if osteoporosis present, intravenous bisphosphonate therapy |
| Gallstones | Low-fat diet; lead an active lifestyle; avoid medications known to cause gallstones (eg, gemfibrozil) |
| Bile reflux | Ensure appropriate length of Roux limb constructed at time of surgery; elevate head of bed >30 degrees (pillows or wedge); no oral intake 2–3 h before going to bed; avoid dietary triggers (spice; large, fatty, or sugary meals; large amounts of liquid at a time); ingesting appropriate food (eg, soft, dry cracker, or Greek yoghurt) may help soothe and carry bile downwards; consider bile acid sequestrants and sucralfate |
| Persistent nausea and vomiting | Assess thiamine levels, replace (oral or intravenous) when needed; avoid dairy; eat easy to digest, non-offensive foods; consider ondansetron wafers when necessary |
| Early satiety | Eat several small meals throughout the day; set a timer to ensure meals are not skipped |
| Weight loss | Weight loss (of around 15–20%) ^{55,64,70} is expected after a total gastrectomy but stabilises in 3–6 months; eat at least six to eight smaller meals per day and snack frequently; include protein-fortified or high-calorie (but low-fat) foods |

Table: Postgastrectomy complications and treatment recommendations

important to review the original histology: β -catenin and p120-catenin can be used to confirm lobular phenotype; p120-catenin shows cytoplasmic staining (membranous in invasive breast carcinoma of no special type and ductal carcinoma in situ); and β -catenin is negative in lobular neoplasia.^{66,67}

Long-term sequelae and follow-up

Optimally, patients undergoing prophylactic total gastrectomy should receive lifelong follow-up with an experienced multidisciplinary team to monitor for long-term sequelae including nutritional, hormonal, immune, neurocognitive, pharmacokinetic, and psychological effects.^{66,68} Postgastrectomy symptoms and current treatment options are described in the table.^{69,70} Patients should also be educated about symptoms of late internal herniation: an urgent, potentially life-threatening complication that can occur at any time after total gastrectomy.

Several HDGC and LBC advocacy organisations support affected families, including No Stomach For Cancer, Hereditary Diffuse Gastric Cancer Advocacy, DeGregorio Family Foundation, and The Lobular Breast Cancer Alliance.

Drug absorption

A total gastrectomy introduces a great deal of uncertainty surrounding the use of solid oral medicines. Patients often have to remind their health-care providers that medications need to be reconsidered after gastrectomy (panel 4).

The reconfiguration of the gastrointestinal tract allows for mixing of bile salts with ingested material, but the process is delayed, affecting solubility of medicines. Additionally, bypassing the stomach and proximal small intestine reduces the surface area available for drug absorption, alters onset of action and availability of intestinal drug transporters and enzymes, and impairs cycling of medications such as the oral contraceptive pill.

Poor tablet and capsule disintegration warrants substitution with liquids, or chewable or dispersible formulations. Caution needs to be exercised with liquids because the high sugar content can cause dumping syndrome, and dispersible tablets might cause abdominal discomfort. In some circumstances, crushing tablets or opening capsules is advisable. Delayed-release medication should be avoided, in view of the decreased functional length of the small intestine. Alternative

For more on **No Stomach For Cancer** see <https://www.nostomachforcancer.org>

For more on **Hereditary Diffuse Gastric Cancer Advocacy** see <https://www.hereditarydiffusegastriccancer.org>

For more on **DeGregorio Family Foundation** see <https://www.degregorio.org>

For more on **The Lobular Breast Cancer Alliance** see <https://lobularbreastcancer.org>

Panel 4: General pharmacological recommendations

- Inform all patients about altered absorption of medicines after total gastrectomy
- Substitute solid oral medication with chewable, dispersible, or liquid preparations
- Consider other routes of administration: sublingual, topical, vaginal, rectal, and parenteral
- Recommend patients crush tablets, or open capsules and ingest contents separately, when no other dosage forms exist and it is safe to do so
- Use alternative contraception rather than the oral contraceptive pill because of impaired absorption
- Where possible, avoid medicines that irritate the intestinal mucosa (eg, non-steroidal anti-inflammatory drugs, corticosteroids, oral bisphosphonates, aspirin, specific antibiotics, and potassium chloride)
- Avoid medication likely to cause gallstones (eg, gemfibrozil)
- Seek alternatives to medicines requiring an acidic environment for absorption (eg, carbamazepine, azole antifungal agents, phenytoin, and selegiline)
- Avoid extended and other delayed-release formulations
- Assess drug–nutrient interactions (eg, iron and calcium) as patients supplement post-surgery to avoid nutritional deficiencies
- Give special attention to the quantity and effects of alcohol
- Exert caution when prescribing medicines with a narrow therapeutic window

See Azran and colleagues⁷³ for further details.

medicines to those requiring an acidic environment for sufficient absorption (eg, azole antifungal agents) should also be sought. Conversely, the increased pH of the intestinal tract will increase exposure to a small number of medications (weak acids), including non-steroidal anti-inflammatory drugs. Other analgesics should be prescribed where possible, and drugs that irritate the intestinal wall should be avoided (eg, aspirin, oral bisphosphonates, and doxycycline).⁷¹

The variability in absorption and effectiveness of oral medicines necessitates regular clinical assessment and review of medicines (table). Favourable administration routes should be explored, including sublingual, transdermal, vaginal or rectal, and injectable preparations.

Sexuality and fertility

Both total gastrectomy and bilateral mastectomy can have substantial effect on sexuality for patients.⁷² For example, changes to the digestive system affect eating, drinking, and bowel habits, which might interfere with intimate relationships and self-confidence. Postprandial fullness, bloating, diarrhoea, dumping syndrome, and altered alcohol tolerance can all affect sexuality. It is helpful to include an obstetrician or gynaecologist, and a specialist in maternal medicine, in the care of women with HDGC.

Women who do not wish to achieve pregnancy can be offered an intrauterine device or other form of contraception that does not require gastrointestinal absorption. Those who do wish to achieve pregnancy should be counselled about preimplantation genetic diagnosis and provided with nutritional counselling before and during pregnancy. An interval of at least 6–12 months

Search strategy and selection criteria

We searched PubMed using the search terms “hereditary diffuse gastric cancer”, “hereditary lobular breast cancer”, “germline *CDH1*”, and “germline *CTNNA1*” for non-review articles published from the date the previous International Gastric Cancer Linkage Consortium Hereditary Diffuse Gastric Cancer guidelines were accepted for publication (March 18, 2015) until Jan 1, 2020. Only English language manuscripts were assessed for inclusion in the manuscript.

after surgery is recommended to allow for weight stabilisation and nutritional recovery. Pregnancies after total gastrectomy appear to be normal,⁷³ although caution is nevertheless warranted because pregnancies after bariatric surgery show an increased risk of adverse perinatal outcomes, such as preterm births, small-for-gestational-age babies, and babies being admitted to the intensive care unit.⁷⁴

Future research

Numerous questions remain about the early molecular and cellular events that lead to progressive disease in *CDH1* pathogenic mutation carriers, in particular the genetic and epigenetic triggers that shift signet ring cells from indolent to invasive behaviour. Other priority areas for future research include individual risk assessment and disease modifiers, *CDH1* and *CTNNA1* variant of unknown significance pathogenicity determination, genotype–phenotype correlations, chemoprevention methods,⁷⁵ and improved methods of endoscopic surveillance (appendix p 11–12).

Conclusion

HDGC risk reduction is a multidisciplinary process that requires shared decision-making with patients at each stage of the process in order to achieve optimal long-term results. Prophylactic total gastrectomy is still the cornerstone of HDGC management. However, knowledge surrounding endoscopic abnormalities and signet ring cell carcinoma detection rates in families with HDGC is improving. Therefore, confidence is increasing that endoscopic surveillance in expert centres could be safely offered to patients who wish to postpone surgery, or to those whose risk is not well defined, for example, when pathogenic *CDH1* variants are found in the absence of a family history of DGC.⁷⁶

Contributors

VRB, FC, DGC, CO, JLDA, JMvD, and NH led an expert writing group; CO, DGC, JLDA, DGH, NH, RSvDP, and FC chaired focus group meetings; KLH led the pharmacology section; KLH, RSvDP, JA, PRB, TMB, AB, ACa, ACh, KECS, JLD, DDP, RCF, JMF, KG, IG, RHH, PK, SSK, AL, PFM, TN, SP, JR, HS, MS, MT, TU, HY, H-KY, and JW were members of a writing group. DGC, JLDA, JMvD, KLH, CO, RSvDP, PRB, TMB, ACa, KECS, JLD, MdP, JMF, IG, DGH, PK, SK, PFM, SP, JR, HS, TU, HKY, ACa, JF, PG, KP, and RS presented at the Wānaka meeting. RSvDP, MML, KP, and AER made special contributions to meeting

design. All other authors contributed to the focus groups at the consensus meeting. PG compiled and integrated the manuscript drafts and is the lead author. The final manuscript was reviewed by all authors.

Declaration of interests

PRB reports personal fees from AstraZeneca, Janssen, and Roche Diagnostics, and non-financial support from Geneticancer, outside the submitted work. DGH is founder and chief marketing officer of Contextual Genomics. The work of Contextual Genomics in no way overlaps with the topics of this Review. LZ received other support from Future Technology Research, Roche Diagnostics Asia Pacific, Beijing Genomics Institute, and Illumina, outside the submitted work. A family member of LZ has a leadership position and ownership interest in the Shanghai Genome Centre. All other authors declare no competing interests.

Acknowledgments

These guidelines were financially supported by No Stomach for Cancer, the DeGregorio Foundation, the DD & DF Heads Charitable Trust, and the University of Otago. PG was supported by a New Zealand Health Research Council Programme grant (17/610). CO was supported by the Portuguese Foundation for Science and Technology grant ref. POCI-01-0145-FEDER-30164 (3DChroMe). KLH, HF, and MDM are HDGC patient advocates. We thank Bronwyn Carlisle (University of Otago, Dunedin, New Zealand), for assistance with figure preparation, and the Piho whānau (Dunedin, New Zealand), Cindy Chelcun (Wallingford, CT, USA), and Brian Chelcun (Brooklyn, NY, USA), for their support.

References

- Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998; **392**: 402–05.
- Hansford S, Kaurah P, Li-Chang H, et al. Hereditary diffuse gastric cancer syndrome: *CDH1* mutations and beyond. *JAMA Oncol* 2015; **1**: 23–32.
- Lecuit T, Yap AS. E-cadherin junctions as active mechanical integrators in tissue dynamics. *Nat Cell Biol* 2015; **17**: 533–39.
- Majewski IJ, Kluij I, Cats A, et al. An α -E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. *J Pathol* 2013; **229**: 621–29.
- Lowstuter K, Espenschied CR, Sturgeon D, et al. Unexpected *CDH1* mutations identified on multigene panels pose clinical management challenges. *JCO Precis Oncol* 2017; **1**: 1–12.
- van der Post RS, Vogelaa IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline *CDH1* mutation carriers. *J Med Genet* 2015; **52**: 361–74.
- Pai M, Iorio A, Meerpohl J, et al. Developing methodology for the creation of clinical practice guidelines for rare diseases: a report from RARE-Bestpractices. *Rare Dis* 2015; **3**: e1058463.
- Schünemann HJ, Zhang Y, Oxman AD. Distinguishing opinion from evidence in guidelines. *BMJ* 2019; **366**: l4606.
- Balslem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol* 2011; **64**: 401–06.
- Lee K, Krempely K, Roberts ME, et al. Specifications of the ACMG/AMP variant curation guidelines for the analysis of germline *CDH1* sequence variants. *Hum Mutat* 2018; **39**: 1553–68.
- Caldas C, Carneiro F, Lynch HT, et al. Familial gastric cancer: overview and guidelines for management. *J Med Genet* 1999; **36**: 873–80.
- Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015; **17**: 405–24.
- Carneiro F, Guilford P, Oliveira C, van der Post R. Hereditary diffuse gastric cancer. WHO Classification of Tumours Editorial Board Digestive system tumours, 5th edn. Lyon, France: International Agency for Research on Cancer, 2019.
- Roberts ME, Ranola JMO, Marshall ML, et al. Comparison of *CDH1* penetrance estimates in clinically ascertained families vs families ascertained for multiple gastric cancers. *JAMA Oncol* 2019; **5**: 1325.
- Xicola RM, Li S, Rodríguez N, et al. Clinical features and cancer risk in families with pathogenic *CDH1* variants irrespective of clinical criteria. *J Med Genet* 2019; **56**: 838–43.
- Petridis C, Arora I, Shah V, et al. Frequency of pathogenic germline variants in *CDH1*, *BRCA2*, *CHEK2*, *PALB2*, *BRCA1*, and *TP53* in sporadic lobular breast cancer. *Cancer Epidemiol Biomarkers Prev* 2019; **28**: 1162–68.
- Hakkaart C, Ellison-Loschmann L, Day R, et al. Germline *CDH1* mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. *Fam Cancer* 2019; **18**: 83–90.
- Obermair F, Rammer M, Burghofer J, et al. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a *CDH1* c.687+1G>A germline mutation and review of the literature. *Fam Cancer* 2019; **18**: 253–60.
- Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 15th edn. Tokyo, Japan: Kanehara Shuppan, 2017.
- Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; **64**: 31–49.
- Gullo I, Devezas V, Baptista M, et al. Phenotypic heterogeneity of hereditary diffuse gastric cancer: report of a family with early-onset disease. *Gastrointest Endosc* 2018; **87**: 1566–75.
- Eijzenga W, Hahn DE, Aaronson NK, Kluij I, Bleiker EM. Specific psychosocial issues of individuals undergoing genetic counseling for cancer - a literature review. *J Genet Couns* 2014; **23**: 133–46.
- Muir J, Aronson M, Esplen MJ, Pollett A, Swallow CJ. Prophylactic total gastrectomy: a prospective cohort study of long-term impact on quality of life. *J Gastrointest Surg* 2016; **20**: 1950–58.
- Kaurah P, Talhouk A, MacMillan A, et al. Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. *Fam Cancer* 2019; **18**: 429–38.
- Hallowell N, Lawton J, Badger S, et al. The psychosocial impact of undergoing prophylactic total gastrectomy (PTG) to manage the risk of hereditary diffuse gastric cancer (HDGC). *J Genet Couns* 2017; **26**: 752–62.
- Katona BW, Clark DF, Domchek SM. *CDH1* on multigene panel testing: look before you leap. *J Natl Cancer Inst* 2020; **112**: 330–34.
- Huynh JM, Laukaitis CM. Panel testing reveals nonsense and missense *CDH1* mutations in families without hereditary diffuse gastric cancer. *Mol Genet Genomic Med* 2016; **4**: 232–36.
- Oliveira C, Senz J, Kaurah P, et al. Germline *CDH1* deletions in hereditary diffuse gastric cancer families. *Hum Mol Genet* 2009; **18**: 1545–55.
- Melo S, Figueiredo J, Fernandes MS, et al. Predicting the functional impact of *CDH1* missense mutations in hereditary diffuse gastric cancer. *Int J Mol Sci* 2017; **18**: 2687.
- Vogelaar IP, van der Post RS, van Krieken JHJ, et al. Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. *Eur J Hum Genet* 2017; **25**: 1246–52.
- Fewings E, Larionov A, Redman J, et al. Germline pathogenic variants in *PALB2* and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without *CDH1* mutation: a whole-exome sequencing study. *Lancet Gastroenterol Hepatol* 2018; **3**: 489–98.
- Sahasrabudhe R, Lott P, Bohorquez M, et al. Germline mutations in *PALB2*, *BRCA1*, and *RAD51C*, which Regulate DNA recombination repair, in patients with gastric cancer. *Gastroenterology* 2017; **152**: 983–86.
- Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *J Med Genet* 2010; **47**: 436–44.
- van der Post RS, Vogelaa IP, Manders P, et al. Accuracy of hereditary diffuse gastric cancer testing criteria and outcomes in patients with a germline mutation in *CDH1*. *Gastroenterology* 2015; **149**: 897–906.
- Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and *Helicobacter pylori* treatment. *N Engl J Med* 2020; **382**: 427–36.
- Clark DF, Michalski ST, Tondon R, et al. Loss-of-function variants in *CTNNA1* detected on multigene panel testing in individuals with gastric or breast cancer. *Genet Med* 2020; published online Feb 13. DOI:10.1038/s41436-020-0753-1
- Benusiglio PR, Colas C, Guillerme E, et al. Clinical implications of *CTNNA1* germline mutations in asymptomatic carriers. *Gastric Cancer* 2019; **22**: 899–903.

- 38 Jacobs MF, Dust H, Koeppel E, et al. Outcomes of endoscopic surveillance in individuals with genetic predisposition to hereditary diffuse gastric cancer. *Gastroenterology* 2019; **157**: 87–96.
- 39 Mi EZ, Mi EZ, di Pietro M, et al. Comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to *CDH1* mutation status. *Gastrointest Endosc* 2018; **87**: 408–18.
- 40 van der Post RS, van Dieren J, Grelack A, et al. Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. *Gastrointest Endosc* 2018; **87**: 397–404.
- 41 Corso G, Figueiredo J, La Vecchia C, et al. Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect. *J Med Genet* 2018; **55**: 431–41.
- 42 Mann RM. The effectiveness of MR imaging in the assessment of invasive lobular carcinoma of the breast. *Magn Reson Imaging Clin N Am* 2010; **18**: 259–76.
- 43 Sardanelli F, Cozzi A, Trimboli RM, Schiaffino S. Gadolinium retention and breast MRI screening: more harm than good? *AJR Am J Roentgenol* 2020; **214**: 324–27.
- 44 Vreemann S, van Zelst JCM, Schlooz-Vries M, et al. The added value of mammography in different age-groups of women with and without *BRCA* mutation screened with breast MRI. *Breast Cancer Res* 2018; **20**: 84.
- 45 King TA, Pilewskie M, Muhsen S, et al. Lobular Carcinoma in Situ: a 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. *J Clin Oncol* 2015; **33**: 3945–52.
- 46 EviQ. *CDH1* risk management. 2018. <https://www.eviq.org.au/cancer-genetics/adult/risk-management/1090-cdh1-risk-management> (accessed Jan 19, 2020).
- 47 NICE. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. 2019. <https://www.nice.org.uk/guidance/cg164> (accessed Jan 19, 2020).
- 48 Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in *BRCA* mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. *Ann Oncol* 2016; **27** (suppl 5): 103–10.
- 49 NCCN. Clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast, ovarian and pancreatic. 2019 https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf (accessed Jan 19, 2020).
- 50 van Zelst JCM, Mus RDM, Woldring G, et al. Surveillance of women with the *BRCA1* or *BRCA2* mutation by using biannual automated breast US, MR imaging, and mammography. *Radiology* 2017; **285**: 376–88.
- 51 Geisel J, Raghu M, Hooley R. The role of ultrasound in breast cancer screening: the case for and against ultrasound. *Semin Ultrasound CT MR* 2018; **39**: 25–34.
- 52 Luveta J, Parks RM, Heery DM, Cheung K-L, Johnston SJ. Invasive lobular breast cancer as a distinct disease: implications for therapeutic strategy. *Oncol Ther* 2019; published online Dec 24. DOI:10.1007/s40487-019-00105-0.
- 53 Hebbard PC, Macmillan A, Huntsman D, et al. Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. *Ann Surg Oncol* 2009; **16**: 1890–95.
- 54 Chen Y, Kingham K, Ford JM, et al. A prospective study of total gastrectomy for *CDH1*-positive hereditary diffuse gastric cancer. *Ann Surg Oncol* 2011; **18**: 2594–98.
- 55 Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS. Prophylactic total gastrectomy for individuals with germline *CDH1* mutation. *Surgery* 2011; **149**: 347–55.
- 56 Hüneburg R, Marwitz T, van Heteren P, et al. Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in *CDH1* mutation positive patients. *Endosc Int Open* 2016; **4**: e1305–10.
- 57 Rocha JP, Gullo I, Wen X, et al. Pathological features of total gastrectomy specimens from asymptomatic hereditary diffuse gastric cancer patients and implications for clinical management. *Histopathology* 2018; **73**: 878–86.
- 58 Humar B, Fukuzawa R, Blair V, et al. Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. *Cancer Res* 2007; **67**: 2480–89.
- 59 Straatman J, van der Wielen N, Cuesta MA, de Lange-de Klerk ES, Jansma EP, van der Peet DL. Minimally invasive versus open total gastrectomy for gastric cancer: a systematic review and meta-analysis of short-term outcomes and completeness of resection: surgical techniques in gastric cancer. *World J Surg* 2016; **40**: 148–57.
- 60 Wang W, Zhang X, Shen C, Zhi X, Wang B, Xu Z. Laparoscopic versus open total gastrectomy for gastric cancer: an updated meta-analysis. *PLoS One* 2014; **9**: e88753.
- 61 Thompson IW, Day DW, Wright NA. Subnuclear vacuolated mucous cells: a novel abnormality of simple mucin-secreting cells of non-specialized gastric mucosa and Brunner's glands. *Histopathology* 1987; **11**: 1067–81.
- 62 Rubio CA. Five types of pyloric cells in the antral mucosa of the stomach. *Pathol Res Pract* 1992; **188**: 157–61.
- 63 Carneiro F, Fukayama M, Grabsch HI, Yasui W. Gastric adenocarcinoma. WHO Classification of Tumours Editorial Board Digestive system tumours, 5th edn. Lyon, France: International Agency for Research on Cancer, 2019.
- 64 van der Kaaij RT, van Kessel JP, van Dieren JM, et al. Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer. *Br J Surg* 2018; **105**: e176–82.
- 65 Kluij I, Siemerink EJ, Ausems MG, et al. *CDH1*-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling. *Int J Cancer* 2012; **131**: 367–76.
- 66 Canas-Marques R, Schnitt SJ. E-cadherin immunohistochemistry in breast pathology: uses and pitfalls. *Histopathology* 2016; **68**: 57–69.
- 67 Pinder SE, Shaaban AM. In situ lobular proliferations of the breast. *Diagn Histopathol* 2018; **24**: 58–63.
- 68 Busetto L, Dicker D, Azran C, et al. Practical recommendations of the obesity management task force of the European Association for the Study of Obesity for the post-bariatric surgery medical management. *Obes Facts* 2017; **10**: 597–632.
- 69 Flores-Guerrero JL, Minovic I, Groothof D, et al. Association of plasma concentration of vitamin B12 with all-cause mortality in the general population in the Netherlands. *JAMA Netw Open* 2020; **3**: e1919274.
- 70 Strong VE, Gholami S, Shah MA, et al. Total gastrectomy for hereditary diffuse gastric cancer at a single center: postsurgical outcomes in 41 patients. *Ann Surg* 2017; **266**: 1006–12.
- 71 Azran C, Wolk O, Zur M, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. *Obes Rev* 2016; **17**: 1050–66.
- 72 Gopie JP, Mureau MA, Seynaeve C, et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. *Fam Cancer* 2013; **12**: 479–87.
- 73 Kaurah P, Fitzgerald R, Dwerryhouse S, Huntsman DG. Pregnancy after prophylactic total gastrectomy. *Fam Cancer* 2010; **9**: 331–34.
- 74 Akhter Z, Rankin J, Ceulemans D, et al. Pregnancy after bariatric surgery and adverse perinatal outcomes: a systematic review and meta-analysis. *PLoS Med* 2019; **16**: e1002866.
- 75 Bougen-Zhukov N, Nouri Y, Godwin T, et al. Allosteric AKT inhibitors target synthetic lethal vulnerabilities in E-cadherin-deficient cells. *Cancers (Basel)* 2019; **11**: e1359.
- 76 van Dieren JM, Kodach LL, den Hartog P, et al. Gastroscopic surveillance with targeted biopsies compared with random biopsies in *CDH1* mutation carriers. *Endoscopy* 2020; published online May 14. DOI:10.1055/a-1157-8678.

© 2020 Elsevier Ltd. All rights reserved.